Showing 1 - 20 results of 3,330 for search '(( lesion ((we decrease) OR (a decrease)) ) OR ( a ((larger decrease) OR (marked decrease)) ))', query time: 0.56s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Pathologically confirmed colon lesions. by Sarah E. Copeland (13951506)

    Published 2024
    “…A modest 2-fold overexpression of MAD1 in murine colon resulted in decreased p53 expression and increased mitotic defects consistent with CIN. …”
  8. 8
  9. 9

    Supplementary Material for: Decreased Lactococcus lactis and propionic acid in feces of patients with Moyamoya disease: Possible implications of immune dysregulation by figshare admin karger (2628495)

    Published 2025
    “…Introduction: Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive steno-occlusive lesions in the terminal portion of the internal carotid artery. …”
  10. 10

    Biases in larger populations. by Sander W. Keemink (21253563)

    Published 2025
    “…<p>(<b>A</b>) Maximum absolute bias vs the number of neurons in the population for the Bayesian decoder. …”
  11. 11
  12. 12
  13. 13

    The sagittal view of T2-weighted Magnetic Resonance Imaging represented a mild decrease in spinal cord diameter without any other lesions at first admission. by Hossein Pourmontaseri (19329565)

    Published 2025
    “…<p>The sagittal view of T2-weighted Magnetic Resonance Imaging represented a mild decrease in spinal cord diameter without any other lesions at first admission.…”
  14. 14

    The sagittal view of T2-weighted Magnetic Resonance Imaging represented a mildly decreased spinal cord diameter without any other lesions at follow-up. by Hossein Pourmontaseri (19329565)

    Published 2025
    “…<p>The sagittal view of T2-weighted Magnetic Resonance Imaging represented a mildly decreased spinal cord diameter without any other lesions at follow-up.…”
  15. 15

    <b>Dihydroxyacetone decreases the dATP pool, inducing replication stress and genomic instability in BEAS-2B cells</b> by Saddam Hussain (22282372)

    Published 2025
    “…Evaluation of DNA damage response showed increased levels of pChk2 and pP53, demonstrating activation of double strand break response. Using a DNA fiber assay we observed decreased replication fork progression, which coincided with increased micronuclei formation. …”
  16. 16

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  17. 17

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 18

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 19
  20. 20